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Abstract
Background: International travel plays a role in the spread of HIV-1 across Europe. It is, however, not known
whether international travel is more important for spread of the epidemic as compared to endogenous infections
within single countries. In this study, phylogenetic associations among HIV of newly diagnosed patients were
determined across Europe.
Results: Data came from the SPREAD programme which collects samples of newly diagnosed patients that are
representative for national HIV epidemics. 4260 pol sequences from 25 European countries and Israel collected in
2002–2007 were included.
We identified 457 clusters including 1330 persons (31.2% of all patients). The cluster size ranged between 2 and 28.
A number of 987 patients (74.2%) were part of a cluster that consisted only of patients originating from the same
country. In addition, 135 patients (10.2%) were in a cluster including only individuals from neighboring countries.
Finally, 208 patients (15.6%) clustered with individuals from countries without a common border. Clustering with
patients from the same country was less prevalent in patients being infected with B subtype (P-value <0.0001), in
men who have sex with men (P-value <0.0001), and in recently infected patients (P-value =0.045).
Conclusions: Our findings indicate that the transmission of HIV-1 in Europe is predominantly occurring between
patients from the same country. This could have implications for HIV-1 transmission prevention programmes.
Because infections through travelling between countries is not frequently observed it is important to have good
surveillance of the national HIV-1 epidemics.
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Background
Travel and migration have contributed to the world-wide
spread of HIV-1. For instance, HIV was introduced in the
America’s through travel and migration from Africa and
Haiti in the 1960s [1]. Travel has also played a role in the
early spread of HIV in East-Africa. A phylogenetic study
that included geographic information found that the HIV
epidemic spread more rapidly in areas in East-Africa with
a good infrastructure that facilitates traveling [2]. Moreo-
ver, we recently showed that within Europe Mediterranean
countries are a source of HIV-1 subtype B infections for
other European countries [3].
Although travel and migration played a key role in the
early spread of HIV, it is not known to what extent travel
explains current transmission of HIV. On the one hand,
the importance of travel may have declined over the
years, because travel from sub-Saharan Africa may have
decreased due to stricter European immigration laws.
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But also among native-born Europeans, travel may have
become less important for the spread of HIV. In Europe,
the HIV prevalence is generally low, and stable at 0.2%
over the last decade [4] and is concentrated mainly in
specific risk groups (men who have sex with men
(MSM) and injection drug users) [5]. Because the HIV
epidemic is well-spread in all European countries, many
transmissions could take place within a country. On the
other hand, the role of travel in transmission of HIV-1
may also have increased further in recent years. Inter-
national travelling has become easier within Europe in
the last decade because of low cost airlines and the ab-
sence of border control between most countries.
In this study we used data from the pan-European
SPREAD project. SPREAD includes individuals newly di-
agnosed with a HIV-1 infection that are representative
for the risk group and geographical distribution of the
HIV epidemic in participating countries [6,7]. By perfor-
ming phylogenetic analyses on this data we estimated
the proportion of individuals newly diagnosed with HIV
that was infected within their own country.
Results
Characteristics
A total of 4,260 patients newly diagnosed with HIV-1
were included. The characteristics of these patients are
summarized in Table 1. The most commonly reported
transmission risk groups were MSM (48%), followed by
heterosexuals (35%) and injection drug users (8%). Most
patients were male (79%). The most frequently found
subtypes were B (66%), A (11%) and C (7%). Other sub-
types or circulating recombinant forms were CRF02_AG
(5%), G (3%), F (2%), and other (4%). A proportion of
1.9% of the sequences could not be classified. The pro-
portion of subtype B was ranging among the countries
between 14.3% in Latvia and 95% in Slovenia. We previ-
ously published a more detailed analysis of the subtype
distribution per country [8]. Nearly one third (29%) of
patients were defined as recently infected (<1 year). The
median CD4 cell count 354 cells/mm3 (IQR: 181–540),
which indicates that approximately half of the included
patients were diagnosed at a stage of their infection where
they were eligible to receive antiretroviral treatment.
The number of patients per country of residence was for
Austria 138, for Belgium 340, for Bulgaria 2, for Croatia
15, for Cyprus 55, for Czech Republic 325, for Denmark
295, for Finland 95, for Germany 685, for Greece 185, for
Ireland 93, for Israel 119, for Italy 197, for Latvia 72, for
Lithuania 11, for Luxembourg 52, for the Netherlands 97,
for Norway 118, for Poland 193, for Portugal 238, for
Romania 67, for Serbia 67, for Slovakia 23, for Slovenia 84,
for Spain 351, and for Sweden 343. Table 2 compares the
risk group distribution per country with surveillance data
of patients newly diagnosed with HIV as reported by the
European Centres for Disease Prevention and Control
(ECDC). Deviations of more than 20% were found in
Cyprus, Poland, Germany and Serbia. It should be noted
that ECDC only included the risk group distribution for
less than 30% of patients from Poland and Cyprus which
can explain the strong deviation found in these countries.
In Germany, we over-sampled MSM (84% in our data vs.
56% in the surveillance data from ECDC). In Serbia we
Table 1 Characteristics of patients
Characteristics Categories Total
patients
Patients 4260
Continent of Origin, no. (%) Western Europe 2361 (55.4)
Eastern Europe &
Central Asia
915 (21.5)
Sub-Saharan Africa 467 (11.0)
Other 517 (12.1)
Baseline values HIV-RNA load, mean
(IQR), log copies/ml
4.8 (4.3-5.3)
CD4 cell count, median
(IQR), cells/mm3
354 (181–540)
Age, mean years (IQR) 36.3 (29–42)
Gender, no. (%) male 3361 (78.9)
Risk group, no. (%) Men having Sex
with Men (MSM)
2061 (48.4)
Heterosexual contact 1477 (34.7)
Injection drug use 347 (8.1)
Other 39 (0.9)
unknown 336 (7.9)
CDC stage, no. (%) A and B 3537 (83.0)
C 516 (12.1)
Subtype, no. (%) B 2820 (66.2)
A 477 (11.2)
C 291 (6.8)
02_AG 197 (4.6)
G 137 (3.2)
F 92 (2.2)
others 167 (3.9)
unassigned 79 (1.9)
non-B 1361 (31.9)
Duration of infection, no.
(%)
<1 year 1228 (28.8)
1-2 years 141 (3.3)
Unknown duration 2891 (67.9)
TDRM, no. (%) present 380 (8.9)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Characteristics
describe patients from whom a baseline HIV-1 genotypic analysis was
available. CDC Centers for disease control and prevention; IQR Interquartile
ranges; MSM Men who have sex with men; TDRM Transmitted drug
resistance mutations.
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over-sampled patients that acquired HIV heterosexually
(49% in our data versus 25% in data from the ECDC).
More than half of all patients (55%) originated from
Western Europe, followed by patients originating from
Eastern Europe and Central Asia (22%) and from Sub-
Saharan Africa (11%). A total of 3322 (77%) patients,
were originating from a country in Europe. A number of
3035 (70%) patients were living in their country of ori-
gin. This ranged between 40.3% to 100%. The lowest
proportions of people living in their country of origen
were found in Israel (40.3%; 44% from Ethiopia), Sweden
(48.2%; 4.5% from Thailand and 4.2% from Ethiopia),
Norway (50.0%; 9.3% from Thailand and 5.9% in
Ethiopia), and 51.1% in Ireland (7.6% from both the
United Kingdom and Zimbabwe).
We found numerous differences between patients
infected with a subtype B virus and patients infected
with a non-B subtype virus. Not surprisingly, patients
infected with a subtype B virus were less often origina-
ting from Sub-Saharan countries (0.7%) as compared to
31.7% in non-B subtype strains (P-value <0.0001). From
this it follows that individuals harboring a subtype B
strain were more often originating from European coun-
tries (89.8%) compared to 50.9% of individuals infected
with a non-B strains (P-value <0.0001). Furthermore, pa-
tients with subtype B strains were more often MSM
(71.9%) and recently infected (34.9%), than patients
infected with a non-B subtype virus (13.6% and 15.9%,
respectively) (both P-values <0.0001).
Phylogenetic analyses
We identified 457 clusters including 1330 persons (31.2%
of all patients). The distribution of the cluster size is shown
in Figure 1. The cluster size ranged between 2 and 28.
Most clusters included two individuals (310 of 457 clusters,
Table 2 Comparison of the proportional HIV risk group distribution in the participating countries of the SPREAD study
with proportional HIV risk group distribution collected in 2007 by the European Centres for Disease Prevention and
Control (ECDC)
Men having Sex with Men (MSM) Heterosexual Injecting drug users
Country SPREAD ECDC Absolute difference SPREAD ECDC Absolute difference SPREAD ECDC Absolute difference
Austria 39.1% 36.9% 2.2% 47.8% 41.1% 6.7% 6.5% 15.2% 8.7%
Belgium 43.5% 27.8% 15.7% 34.4% 40.5% 6.1% 0.9% 2.0% 1.1%
Croatia 60.0% 57.7% 2.3% 20.0% 28.8% 8.8% 13.3% 3.8% 9.5%
Cyprus 49.1% 13.7% 35.4% 45.5% 14.4% 31.1% 0.0% 1.4% 1.4%
Czech Republic 41.8% 63.6% 21.8% 20.0% 23.1% 3.1% 7.7% 9.9% 2.2%
Denmark 44.7% 46.4% 1.7% 45.4% 42.5% 2.9% 5.1% 6.9% 1.8%
Finland 45.3% 36.2% 9.1% 45.3% 40.4% 4.9% 8.4% 6.9% 1.5%
Germany 84.4% 56.0% 28.4% 7.7% 24.1% 16.4% 3.5% 5.5% 2.0%
Greece 67.0% 55.5% 11.5% 21.1% 25.3% 4.2% 2.7% 2.3% 0.4%
Ireland 33.3% 20.5% 12.8% 43.0% 40.7% 2.3% 18.3% 12.8% 5.5%
Israel 39.5% 21.9% 17.6% 46.2% 48.2% 2.0% 13.4% 11.0% 2.4%
Italy 37.6% 25.1% 12.5% 53.3% 49.2% 4.1% 2.5% 8.5% 6.0%
Latvia 8.3% 4.2% 4.1% 33.3% 36.0% 2.7% 38.9% 40.2% 1.3%
Luxembourg 34.6% 36.2% 1.6% 53.8% 38.3% 15.5% 3.8% 14.9% 11.1%
Netherlands 45.4% 62.5% 17.1% 45.4% 30.2% 15.2% 7.2% 1.1% 6.1%
Norway 32.2% 31.0% 1.2% 58.5% 57.3% 1.2% 8.5% 5.2% 3.3%
Poland 37.3% 4.7% 32.6% 28.5% 10.2% 18.3% 26.9% 12.9% 14.0%
Portugal 16.0% 15.0% 1.0% 62.6% 63.5% 0.9% 16.0% 19.4% 3.4%
Romania 14.9% 3.6% 11.3% 53.7% 66.1% 12.4% 3.0% 1.8% 1.2%
Serbia 32.8% 44.0% 11.2% 49.3% 25.3% 24.0% 14.9% 13.2% 1.7%
Slovakia 65.2% 64.1% 1.1% 34.8% 30.8% 4.0% 0.0% 2.6% 2.6%
Slovenia 86.9% 81.1% 5.8% 13.1% 5.4% 7.7% 0.0% 0.0% 0.0%
Spain 53.3% 44.1% 9.2% 27.4% 39.3% 11.9% 8.3% 9.9% 1.6%
Sweden 36.4% 22.0% 14.4% 51.6% 40.7% 10.9% 9.9% 11.6% 1.7%
The numbers may not add up to 100% as the HIV risk group is not always known (most notably this distribution was reported by ECDC for <30% of patients in
Cyprus and Poland).
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67.8%), 112 clusters contained 3–5 persons (24.5%) and 35
clusters contained >5 persons (7.7%).
Patients that were part of a phylogenetic cluster had
different characteristics as compared to patients that
were not in a cluster. First, patients included in any clus-
ter were more frequently infected through MSM (63.2%
in a cluster vs. 41.3% of individuals that did not cluster,
P-value <0.0001). Patients that were part of a cluster
were more frequently infected with subtype B (82.5%;
P-value <0.0001), recently infected (39.5%; P-value <0.0001)
and harbouring a transmitted drug resistance mutation
(10.4%, P-value =0.03) as compared to non-clustering
patients (58.8%, 23.9%, and 8.3%, respectively). We ob-
served a significant increase in cluster frequency among
recently infected individuals from 33% in 2002 to 48%
in 2007 (P-value = 0.002).
Of the clustering patients infected with a subtype B virus,
1013 (92.1%) patients were originating from a European
country. In patients infected with a non-B subtype that
were clustering, a smaller percentage of 63.5% originated
from Europe (P-value <0.0001). Nonetheless, we found
high proportions of patients originating from Europe in
clustering patients infected with subtype F (25 out of 26,
96.2%), subtype A (44 out of 61, 72.1%) and subtype G
(12 out of 19, 63.2%). Most of these patients infected with
subtype F were living in Romania (n = 10) and Italy
(n = 10) and were heterosexually infected (n = 17). Most of
these patients infected with subtype A strains were living
in Greece (n = 12), Latvia (n = 8), Cyprus (n = 6) and
Austria (n = 6). In these patients, transmission through
MSM was the most common route of transmission in pa-
tients from Greece (11 out of 12) and from Cyprus (3 out
of 6), whereas in the other countries subtype A viruses
were mostly transmitted among heterosexual patients.
The 12 patients that were part of a cluster and were
infected with subtype G were living in many different
countries and were mainly heterosexual patients (n = 10).
Most patients (a number of 987, 74.2%) were part
clusters that consisted only of patients originating from
the same country of residence. The largest clusters were
found in Poland (n = 15), Germany (n = 12 and 11), and
the Czech Republic (n = 10). Among the remaining
international clusters containing 343 patients, 135
(10.2%) of patients were in a cluster including only indi-
viduals from neighboring countries (the largest had 10
individuals from Denmark and Germany). Finally, 208
patients (15.6%) clustered with individuals from coun-
tries without a common border (including the largest
cluster of 28 patients). The cluster size of 28 contained
patients mostly living in the Czech Republic (n = 25)
with two patients living in Slovakia and one patient li-
ving in Italy. Of these 28 patients, 24 patients reported
to be MSM. In the 46 international clusters without a
common border, most involved patients living in Spain
(n = 18) or Germany (n = 15).
Table 3 shows the characteristics of the clusters and
the patients involved. The proportion of patients in na-
tional clusters was different compared to international
clusters for several characteristics. First, clustering with
patients from the same residence country was less preva-
lent in patients infected with a B subtype (71.5% of all
clusters) vs. non-B subtypes (87.0% of all clusters;
P-value <0.0001). Also, MSM (68.9%) and recently infec-
ted patients (71.1%) showed less clustering with patients
from the same residence country compared to hetero-
sexuals (86.3%) or injection drug user (84.7%) (P-value
<0.0001) and patients with a chronic or unknown du-
ration of infection (76.2%; P-value =0.045). The presence
or absence of transmitted drug resistance mutations did
not influence the proportions of patients clustering in
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national clusters (74.6 and 74.2%, respectively). In a multi-
variate analyses, the significant difference in proportion of
patients clustering in national clusters only remained for
the risk group characteristic (P-value <0.0001).
In Figure 2, the proportion of patients in national clus-
ters was observed for Central & East-, West- and South
Europe, separately. We saw a statistically significant dif-
ference in proportion of patients in national clusters in
Central & East- (71.7%) and West- (73.5%) and South
Europe (80.0%) (P-value <0.001). Also, when making a
distinction between the different HIV risk groups, there
was a difference between Central & East-, West-, and
South Europe in proportion of patients in clusters with
one country of residence for MSM (P-value =0.007) and
for heterosexuals (P-value =0.024), but not for IDU
(P-value =0.20).
Sensitivity analysis for cluster determination
We performed sensitivity analyses using different cut-off
values for bootstrap values and for genetic distance
(Table 4). When we changed the bootstrap value from
98% to 90%, the number of clusters found increased from
457 to 529, including 1643 persons (38.6% of all patients).
The smaller bootstrap value did not change the percentage
of clusters containing individuals with the same country of
residence (from 83.2 to 82.0%; p = 0.67). The number of
clusters which included persons from neighbouring coun-
tries was also highly comparable (7.9 and 6.8%). When we
changed the genetic distance of 0.03 to a more stringent
value of 0.01, the number of clusters found decreased to
327, including 811 persons (19.0% of all patients). Here,
more clusters contained individuals with the same country
of residence (90.8%; p = 0.002) and a 3.7% of clusters were
found with neighbouring-country-patients.
Discussion
In this large collection of sequences sampled from newly
diagnosed individuals considering representativeness and
large coverage across Europe, we found phylogenetic re-
lationships (clusters) between isolates in one third of the
study individuals. In these clusters, the vast majority of
sequences were sampled from persons living in the same
country. This suggests that a large part of the spread of
HIV-1 in Europe can be explained by transmission of in-
fections taking place between patients within the same
country.
A strength of our study is the data collection that is
performed within the SPREAD programme. The SPREAD
programme is a large and sufficiently powered pan-
European study that has been running since 2002. During
this time the programme included patients newly diag-
nosed with HIV using a predefined strategy. This strategy
allowed us to include patients considering representa-
tiveness for the national HIV epidemic in participating
countries.
However, even though we achieved a very good overall
representativeness of the European HIV-1 epidemic, we
Table 3 Characteristics of clusters and patients
Characteristics Category All
clusters, n
Clusters with one country of
residence, n (%)
Clusters with neighbouring
countries, n (%)
International clusters,
n (%)
Characteristics of clusters
Total 457 380 (83.2) 31 (6.8) 46 (10.1)
Subtype Subtype B 357 291 (81.5) 26 (7.3) 40 (11.2)
Non-B
subtype
100 89 (89.0) 5 (5.0) 6 (6.0)
Characteristics of patients in clusters
Total 1330 987 (74.2) 135 (10.2) 208 (15.6)
Subtype Subtype B 1100 787 (71.5) 119 (10.8) 194 (17.6)
Non-B
subtype
230 200 (87.0) 16 (7.0) 14 (6.1)
Risk group MSM 839 578 (68.9) 103 (12.3) 158 (18.8)
Heterosexuals 278 240 (86.3) 13 (4.7) 25 (9.0)
IDU 85 72 (84.7) 10 (11.8) 3 (3.5)
other 128 97 (75.8) 9 (7.0) 22 (17.2)
seroconverters yes 523 372 (71.1) 61 (11.7) 90 (17.2)
no 807 615 (76.2) 74 (9.2) 118 (14.6)
TDRM yes 134 100 (74.6) 21 (15.7) 13 (9.7)
no 1196 887 (74.2) 114 (9.5) 195 (16.3)
MSM Men who have sex with men; IDU Injection drug users; TDRM Transmitted drug resistance mutations.
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need to acknowledge that it is difficult to exclude the ex-
istence of minor sampling biases in specific countries
and transmission groups. We assessed the representa-
tiveness by comparing the distribution of the transmis-
sion groups in all countries included in SPREAD with
the HIV surveillance data from the European Centre for
Disease prevention and Control (ECDC) (Table 2) and
found that the proportional distribution of the different
transmission groups was very comparable. However,
compared to the data from ECDC, MSM were somewhat
over-represented in some of the countries participating
in SPREAD. In this study, we found MSM having a
lower proportion of clustering patients from one coun-
try. An overrepresentation of MSM would therefore
have resulted in a lower overall proportion of clustering
patients from one country. This confirms our finding
that HIV is mainly spreading within a country.
The results of this study are in agreement with phylo-
genetic studies performed in single European countries
[9,10]. First, a phylogenetic transmission study performed
in Belgium found that local onward transmission of sub-
type B virus contributes to an important extent to the epi-
demic as virtually all patients part of a transmission
cluster were of Caucasian origin [9]. Second, a study from
Switzerland found that clustering was segregated between
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Figure 2 Characteristics of patients in clusters per region in all patients (A), among MSM (B), among heterosexuals (C) and among
IDU (D).
Table 4 Sensitivity analyses on proportion of clusters
containing individuals with the same country of
residence
Bootstrap value Genetic distance
0.01 0.02 0.03
90 Within one country 90.6 84.1 82.0
Neighbouring country 4.5 7.7 7.9
Without common border 4.9 8.3 10.0
98 Within one country 90.8 84.2 83.2
Neighbouring country 3.7 6.9 6.8
Without common border 5.5 9.0 10.1
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different regions in the country, as transmission events oc-
curred preferentially within the same Swiss region [10].
Our study found that patients infected with a non-B
subtype virus were less often found in phylogenetic clus-
ters (17.5%) as compared to patients infected with a sub-
type B virus (39.2%). This finding reflects differences
between patients infected with HIV of non-B subtypes
and patients infected with a B subtype. First, a much
higher proportion of migrants originating from Sub-
Saharan countries are infected with a non-B subtype. A
Dutch modeling study showed that the migrant groups
did not have a large influence on the Dutch HIV epi-
demic, due to the small number of migrants, their rela-
tively moderate sexual risk behavior and low mixing
with the Dutch heterosexuals [11]. This is in concor-
dance with phylogenetic studies in Switzerland which
showed that non-B subtypes are a combined result of
both migration and domestic transmission [12] whereas
the subtype B epidemic is mainly driven by within coun-
try transmission [10]. Second, patients infected with a
non-B subtype are less frequently recently infected
(<1 yr) as compared to patients infected with a subtype
B virus, thus suggesting the possibility to became
infected before they moved to Europe. Because non-B
subtype patients are often chronically infected at time of
diagnosis and have originated from many different coun-
tries, the chance of phylogenetic clustering in these pa-
tients is smaller. Also, patients infected with a non-B
subtype are more often heterosexually infected. Com-
pared to MSM, heterosexual individuals less frequently
receive a HIV test. As a consequence HIV infections are
less likely to be identified in a timely manner in hetero-
sexually infected patients.
In all HIV risk groups, clustering was found mainly
between patients with the same country of residence.
However, differences were seen between the risk groups.
MSM did less often cluster with patients from the same
country than heterosexuals and injection drug users.
This is also reflected in the lower percentage of sero-
converters clustering within a country compared to the
non-seroconverters, which could be ascribed to the fact
that HIV-infected MSM are often diagnosed at an earlier
stage of infection [13]. The less frequently clustering
MSM suggests that MSM more often get infected during
travels to other European countries whereas heterose-
xuals and injection drug users get infected near home.
This is supported by studies reporting an association of
transmission of HIV-1 in injection users with extensive
local epidemics [14,15].
Sensitivity analyses showed that our findings were not
distorted by the arbitrary cut-off values that were used
for the bootstrap values and for the genetic distance.
Using a more stringent genetic distance increased the
percentage of patients clustering with patients living in
the same country. Therefore, the percentage of patients
clustering with patients living in the same country is at
least 83.2% or higher, because the initial genetic distance
used in the main analyses was taken very wide. Larger
bootstrap values did not change the results in our study.
Therefore, these results are generally robust and not
influenced by the level of bootstrap values used in the
cluster definition.
We did not have access to dense samples in which se-
quences from virtually all newly diagnosed HIV-infected
individuals in a particular country are included. We may
therefore have underestimated the size of the clusters or
missed individuals for whom we currently did not iden-
tify a phylogenetically related sequence. This is the rea-
son also why we probably estimated a large number of
small clusters. Nonetheless, we still found that one out
of three individuals was part of a cluster. In addition,
dense sampling is expected not to have changed the re-
sults to a great extent as we achieved a very good overall
representativeness of the European HIV-1 epidemic.
Conclusions
Our findings indicate that the transmission of HIV-1 in
Europe is for a large part occurring between patients
from the same country. These findings have significant
public health implication, as they show that a large part
of all HIV-1 infections in Europe could possibly be
prevented by local interventions.
Methods
Ethics statement
Ethical requirements are fulfilled according to the pro-
cedure described in the EC contract. The procedure dif-
fers among the 32 countries in the network according to
national legislation. Briefly, for each participating hos-
pital or collection center, approval was obtained by the
institutional medical ethical review committee. Addi-
tionally, a written informed consent was obtained for
each patient. In countries where a mandatory surveil-
lance system was already established, legally no informed
consent was needed. All surveillance data were made
anonymous and coded at national level.
Study population
Data came from the SPREAD programme which included
newly diagnosed HIV-1 infected patients of 18 years and
older who had never been exposed to antiretroviral drugs
from 2002–2007. A blood sample had to be collected from
each patient within six months after diagnosis. The sam-
pling strategies were defined in close collaboration with
the national public health institutes in the participating
countries that had access to the latest information on na-
tional HIV epidemics. To obtain representative samples
from every country, the investigators selected individuals
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randomly or according to the national distribution of
transmission risk groups and the geographical distribution
of patients with new diagnoses of HIV-1 infection. Epi-
demiological, clinical, and behavioral data were collected
using a standardized questionnaire within six months of
diagnosis. More details on the sampling strategy are pro-
vided in previous publications from the SPREAD Pro-
gramme [6,7]. Within the SPREAD study, we defined
patients as recently infected when patients had a duration
of infection of less than one year. The duration of infec-
tion could be calculated when a last negative HIV-test was
available 3 years before diagnosis. In these patients, the
date of infection was estimated as the midpoint between
the date of the last negative and first positive test. In
addition, individuals were defined as recently infected if
they had documented negative or indeterminate HIV-1
serological results up to 12 months prior to confirmation
of diagnosis by western blot.
The GenBank accession numbers for the sequences
used in this analysis are listed in the Appendix.
Phylogenetics
HIV-1 subtypes were determined by the Rega subtyping
tool (version 2.0) [16]. The Rega subtyping tool assesses
HIV-subtypes by the construction of phylogenetic trees
with group M pure reference sequences for subtypes
A-D, F-H, J and K. A sequence is classified as a particu-
lar subtype when bootstrap values are >70% without re-
combination in the bootscan, and when they do not
cluster with a circulation recombinant form with boot-
strap >70%.
Isolates suggestive of intersubtype recombination in
protease and reverse transcriptase fragments were ana-
lyzed by SimPlot 3.5.1 software [17]. All sequences were
aligned to consensus sequences from the Los Alamos
Sequence Database using Clustal W as implemented in
the BioEdit software [18]. Sequences were then trimmed
to equal length and the gaps were removed. In order to
remove the influence of convergent evolution at anti-
retroviral drug resistance mutations on the phylogenetic
analysis, we excluded all sites associated with major re-
sistance according to the International AIDS Society-
USA [19]. In protease these positions are 30, 32, 33, 46,
47, 48, 50, 54, 58, 74, 76, 82, 84, 88, and 90. In reverse
transcriptase the following positions were excluded: 41,
62, 65, 67, 69, 70, 74, 75, 77, 100, 101, 103, 106, 108,
115, 116, 151, 181, 184, 188, 190, 210, 215, 219 and 225.
This resulted in 920 nucleotides that were used for
phylogenetic analysis.
Phylogenetic analyses are computationally intensive.
We therefore created two different datasets in order to
analyse subtype B sequences (which is the most com-
mon subtype in Europe [6,7]) separately from non-B
subtype sequences. Subtype C was chosen as out-group
for analysis of sequences of subtype B. Similarly, subtype
B was taken as an out-group for the analysis of non-B
subtypes. Phylogenetic trees were constructed using the
MEGA5 integrated analysis software [20] by maximum
likelihood methods under the general time-reversible
model. The reliability of the maximum likelihood tree
was determined using bootstrapping with 1000 repli-
cates. To identify transmission clusters, the novel me-
thodology for large-scale phylogeny partition was used
[21]. This method identifies transmission chains by con-
jugating the evaluation of node reliability, tree topology
and patristic distance analysis and was validated in a
large Italian cohort [21].
Clustering was based on high bootstrap values (>98%)
and intra-cluster average branch lengths less than 0.03
nucleotide substitutions per site [22]. We feel that these
criteria are suitable for our epidemiological questions,
but we acknowledge that there is no consensus on the
definition of clusters. For this reason and because the
cut-offs for bootstrap values and genetic distances could
impact on clustering, we performed a sensitivity analysis
in which clusters were defined using a less strict boot-
strap value of 90%. In addition, we also did a sensitivity
analysis using stricter cut-off values for the genetic dis-
tances of 0.02 and 0.01.
To study the demographics of the transmission clusters,
we divided the clusters into clusters containing patients
from the same country of residence, clusters with patients
from countries of residence with a common border, and
clusters with patients from different countries of residence
which do not share a common border. We also divided
Europe into three region: Central & East (Bulgaria, Croatia,
Czech Republic, Latvia, Lithuania, Poland, Romania, Serbia,
Slovakia, and Slovenia), West (Austria, Belgium, Denmark,
Finland, Germany, Ireland, Luxembourg, the Netherlands,
Norway, and Sweden), and South (Cyprus, Greece, Italy,
Israel, Portugal, and Spain) to study the demographics of
the transmission clusters geographically.
Statistical analyses
Categorical data were compared using the chi-square test.
Multivariate analyses as well as the time trend analysis
were performed with logistic regression. The univariate
analyses where included in the multivariate analyses by
the forward stepwise method in the SPSS programme.
Appendix
GenBank Accession Numbers:
AJ971093, AJ971102, AJ971103, AJ971106, AJ971107,
AJ971109, AJ971114, AJ971117, AJ971122, AJ971140,
AJ971143, AJ971144, AY694290, AY694313, AY694317,
AY694318, AY694321, AY694322, AY694324, AY694328-
AY694330, AY694338, AY694339, AY694343-AY694345,
AY694350, AY694353, AY694361, AY694362, AY694377,
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AY694382, AY938439, AY938441-AY938447, AY938453,
AY938455, AY938460, AY938463-AY938465, AY938475,
AY938476, AY938482, AY938487, AY938488, AY938490,
AY938492, AY938510, AY938512, AY938513, AY938517,
AY938521, AY938523, AY938531, DQ974841, DQ974844,
DQ974845, DQ974847, DQ974848, DQ974850, DQ9748
53, DQ974854, DQ974857, DQ974858, DQ974863-DQ97
4865, DQ974867-DQ974873, DQ974875-DQ974877, DQ9
74880-DQ974882, DQ974887, DQ974890, DQ974892, DQ
974893, DQ974895-DQ974897, DQ974899, DQ974902-
DQ974906, DQ974908, DQ974910-DQ974912, DQ97492
2-DQ974924, DQ974927-DQ974929, DQ974931, DQ9749
32, DQ974941, DQ974944, DQ974945-DQ974947, DQ97
4951-DQ974953, DQ974955-DQ974963, DQ974965, DQ9
74966, DQ974968, DQ974982-DQ974991, DQ974996-DQ
974998, DQ975003, DQ975011-DQ975015, DQ975018-
DQ975021, DQ975024, DQ975032, DQ975034-DQ975036,
DQ975044, DQ975136, DQ975139-DQ975147, DQ9751
56-DQ975159, DQ975161-DQ975163, DQ975165, DQ975
169, DQ975172, DQ975173, DQ975187, EU248291-EU24
8297, EU248299, EU248300, EU248302, EU248303, EU24
8305-EU248307, EU248309, EU248310, EU248312, EU248
314, EU248315, EU248317, EU248320-EU248323, EU248
325, EU248327, EU248329, EU248331-EU248337, EU248
340, EU248341, EU248343-EU248345, EU248347-EU248
360, EU248363-EU248365, EU248368, EU248371-EU248
373, EU248376-EU248378, EU248382, EU248383, EU248
385-EU248387, EU248389, EU248392, EU248393, EU248
396, EU248399-EU248401, EU248403, EU248404, EU248
406-EU248408, EU248410-EU248412, EU248415-EU248
419, EU248421-EU248426, EU248428, EU248431, EU248
432, EU248435, EU248439-EU248444, EU248446, EU248
448, EU248449, EU248451, EU248453, EU248455-EU248
457, EU248459-EU248461, EU248463-EU248466, EU2484
68-EU248474, EU248476, EU248477, EU248479, EU248
480, EU248483, EU248485, EU248487-EU248490, EU248
492, EU248494-EU248498, EU248500-EU248505, EU248
507, EU248509, EU248512, EU248515, EU248517-EU24
8521, EU248523, EU248526-EU248569, EU248571-EU248
582, EU248584-EU248588, EU673374-EU673397, FJ0307
67, FJ030769, FJ030771, FJ030772, FJ185113-FJ185120, FJ1
85122, FJ185124, FJ185125, FJ185127, GQ398826-GQ39
9141, GQ399143-GQ399892, GQ399894-GQ400280, GQ4
00282-GQ400615, GQ400617-GQ400625, GQ400627-GQ4
00682, GQ400684-GQ400905, GQ400907-GQ400913, GQ
400915-GQ401008, GQ401010-GQ401023, JX299533-JX29
9579, JX299581-JX299666, JX299668-JX299780, JX299782-
JX301162.
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